From Ideas to Drugs
Event details
Date | 05.10.2018 |
Hour | 15:00 › 16:00 |
Speaker | Dr Martine Clozel |
Location | |
Category | Conferences - Seminars |
Martine Clozel will receive a degree honoris causa at the Magistrale. It was the opportunity to invite her for a unique seminar at the School of life sciences.
Martine Clozel, a pediatrician specializing in neonatal intensive care, has an MD degree from Nancy University, France, and received further training in physiology and pharmacology from McGill University, Montreal, and the University of California, San Francisco.
During her 11 years at F. Hoffmann-La Roche Ltd, she initiated the research project on endothelin and endothelin receptor antagonists which led to the discovery and clinical development of bosentan (Tracleer®), tezosentan, clazosentan and other molecules.
She has published over 140 peer-reviewed papers in the fields of endothelial function, endothelin and endothelin receptor antagonists. In 1997 she was awarded the Hoffmann-La Roche Research Prize for her achievements in the field of endothelin research. In 2008, she was honored as “Chevalier dans l’Ordre de la Légion d’Honneur”. In 2015, she was awarded the Tomoh Masaki award for her contribution to endothelin science and successfully discovering several endothelin receptor antagonists, especially Tracleer® (bosentan) and Opsumit® (macitentan), two molecules that each made history in the field of pulmonary arterial hypertension.
In 1997 Martine co-founded Actelion Pharmaceuticals Ltd, where she was Senior Vice President, Chief Scientific Officer and Head of Drug Discovery, Pharmacology & Preclinical Development. Martine was also is a member of the Extended Actelion Executive Committee.
With the sale of Actelion to Johnson & Johnson in June 2017, the drug discovery and early clinical pipeline business was demerged and Idorsia was established. Idorsia, a new biopharmaceutical company, is specialized in the discovery and development of small molecules to provide innovative therapeutic options. Martine retains her role as Chief Scientific Officer. Idorsia has currently 11 molecules in clinical development.
Practical information
- General public
- Free
- This event is internal
Organizer
- Prof. Bart Deplancke
Contact
- Caroline Guinchard